Special Issue

Recent Trends in PET/CT Tracer Development and Multimodal Imaging

Message from the Guest Editors

In the field of research on the development of new radiochemistry methods, innovative radiotracers and imaging agents for PET/CT studies and in vivo optical imaging, including multifunctional imaging agents, there has been major progress during the past decade. Especially in terms of chemoselectivity and labeling efficacy, the availability of imaging agents for preclinical (multimodal) imaging studies has enormously increased. We invite young scientists and principle investigators to contribute original research articles as well as review articles that present modern techniques in PET/CT tracer development, such as multifunctional tracers, and related disciplines concerned with preclinical multimodal imaging in the field of MR, ultrasound, CT or SPECT. Studies should focus on monitoring therapy of various cancer types and thus facilitating translational research. We are interested in original as well as review articles that represent the current role of imaging agent development and multimodal imaging of cancers in facilitating translation into the clinics.

Guest Editors

Prof. Dr. Olaf Prante

Department of Nuclear Medicine, Translational Research Center, Molecular Imaging and Radiochemistry, Friedrich-Alexander University (FAU), 91054 Erlangen, Germany

Prof. Dr. Tobias Bäuerle

Department of Radiology and Preclinical Imaging Platform Erlangen, Friedrich-Alexander University (FAU), 91054 Erlangen, Germany

Deadline for manuscript submissions

closed (30 June 2024)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



mdpi.com/si/91247

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

